NDA 020786 · Chattem Sanofi
Allegra-D 12 Hour Allergy and Congestion
Fexofenadine Hydrochloride, Pseudoephedrine Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Oct 31, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 24, 1997
Approved uses
4
Original approval plus efficacy supplements
Registered trials
99
15 Phase 3, 7 recruiting
FAERS reports
49
12 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 12, 2026.
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchy, watery eyes ▪ itching of the nose or throat temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies reduces swelling of nasal passages temporarily relieves sinus congestion and pressure temporarily restores freer breathing through the nose
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 8, 2015 Supplement 33 · Efficacy LabelLetter
- Jan 24, 2011 Supplement 27 · Efficacy LabelLetter
- May 12, 2003 Supplement 14 · Efficacy · priority review LabelLetter
- Dec 24, 1997 Original approval · Type 4 - New Combination Review
1 products under this application
- ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION · FEXOFENADINE HYDROCHLORIDE 60MG; PSEUDOEPHEDRINE HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Fexofenadine" as an intervention, any sponsor and status, largest first.
- The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial InfarctionPivotal-lookingRecruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07381803 · 2,804 participants (planned) · Start Jan 27, 2025 · Primary completion Dec 2026
Drug: Fexofenadine 60 Mg Oral Tablet; Placebo · For: Zhejiang University
Sites: Hangzhou, China
- Long-Term Safety Performance of Fexofenadine in AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00045955 · 1,200 participants (planned) · Start Feb 2002 · Primary completion Nov 2003
Drug: Fexofenadine, Comparator = Montelukast · For: Asthma
Sites: Bridgewater, New Jersey
SanofiSanofi (SNY)
NCT00637611 · 1,010 participants · Start Feb 2003
Drug: Fexofenadine HCl · For: Seasonal Allergic Rhinitis
Sites: Bridgewater, New Jersey
- Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00044824 · 1,000 participants (planned) · Start Feb 2002 · Primary completion Oct 2003
Drug: Fexofenadine · For: Asthma
Sites: Bridgewater, New Jersey; Costa Rica, Costa Rica; Guatemala City, Guatemala · 7 sites in all
- Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00044811 · 1,000 participants (planned) · Start Mar 2002 · Primary completion Oct 2003
Drug: Fexofenadine · For: Asthma
Sites: Bridgewater, New Jersey; Costa Rica, Costa Rica; Guatemala City, Guatemala · 7 sites in all
- Fluticasone Furoate Nasal Spray Versus Oral FexofenadinePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00435461 · 1,000 participants · Start Dec 20, 2006 · Primary completion Feb 1, 2007
Drug: Fluticasone furoate and fexofenadine · For: Rhinitis, Allergic, Seasonal
Sites: Austin, Texas; Kerrville, Texas; New Braunfels, Texas · 6 sites in all
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783146 · 728 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00783211 · 722 participants · Start Aug 1, 2004 · Primary completion Oct 1, 2004
Drug: desloratadine; fexofenadine and 1 more · For: Seasonal Allergic Rhinitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product quality issue8
- drug ineffective7
- diarrhoea4
- dizziness4
- extra dose administered4
- headache4
- nausea4
- chest discomfort2
- constipation2
- ear pain2
- fatigue2
- gastrointestinal disorder2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2014 | 11 |
| 2015 | 13 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
- Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.
Ansotegui IJ, Bousquet J, Canonica GW, et al. · Curr Med Res Opin 2024 · Systematic Review
- Repurposing fexofenadine as a promising candidate for diabetic kidney disease: randomized clinical trial.
El-Fatatry BM, El-Haggar SM, Ibrahim OM, et al. · Int Urol Nephrol 2024 · Randomized Controlled Trial
- Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.
Phinyo P, Koompawichit P, Nochaiwong S, et al. · J Allergy Clin Immunol Pract 2021 · Research Support, Non-U.S. Gov't, Network Meta-Analysis
- Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.
Huang CZ, Jiang ZH, Wang J, et al. · BMC Pharmacol Toxicol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- [The effect of combined therapy on seasonal allergic rhinitis].
Liu Y, Ye XJ, Zhao CL, et al. · Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016 · Randomized Controlled Trial
Sponsor: Chattem Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.